This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits

California-based Foresite Capital Management VI sold 585,000 shares of Edgewise Therapeutics in the third quarter. The overall position value fell by about $7.67 million from the previous period. The ...

Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.
American Association of Individual Investors

Why Edgewise Therapeutics, Inc.’s (EWTX) Stock Is Up 20.17%

As of Wednesday, December 24, Edgewise Therapeutics, Inc.’s EWTX share price has surged by 20.17%, which has investors questioning if this is right time to sell.
Le Lézard

Italfarmaco and JCR Pharmaceuticals Announce Commercialisation Agreement for Givinostat in Japan and Strategic Collaboration in Rare Disease

Italfarmaco S.p.A. and JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), today announced an exclusive licensing agreement for the development and commercialisation of givinostat in Japan. Under the ...